FDA Drug Recalls

Recalls / Class II

Class IID-0721-2021

Product

Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL) NDC 0121-0868-16; b) 2 fl oz (60 mL) NDC 0121-0868-02; Manufactured by: Pharmaceutical Associates, Inc. Greenville, SC 29605

Brand name
Nystatin
Generic name
Nystatin
Active ingredient
Nystatin
Route
Oral
NDC
0121-0868
FDA application
ANDA203621
Affected lot / code info
Lots: a) C98F, C990 Exp. 30SEP2022, C9C2 Exp. 31OCT2022; b) C9E1 Exp. 31OCT2022

Why it was recalled

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Recalling firm

Firm
PAI Holdings, LLC. dba Pharmaceutical Associates Inc
Manufacturer
PAI Holdings, LLC dba PAI Pharma
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1700 Perimeter Rd, N/A, Greenville, South Carolina 29605-5252

Distribution

Quantity
a) 1002 cases (12 bottles/case); b) 458 cases (24 bottles/case)
Distribution pattern
Distributed Nationwide in the USA

Timeline

Recall initiated
2021-07-29
FDA classified
2021-08-12
Posted by FDA
2021-08-18
Terminated
2022-12-02
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0721-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Nystatin · FDA Drug Recalls